Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
暂无分享,去创建一个
K S Panageas | G. Hortobagyi | C. Hudis | L. Norton | M. Theodoulou | V. Valero | M. Moasser | F. Esteva | M. Cristofanilli | M. Moynahan | K. Panageas | A. Seidman | G. Hortobagyi | M. Dickler | L. Tan | L Norton | V Valero | G N Hortobagyi | T. Gilewski | G. D’Andrea | N. Sklarin | E. Rivera | M Cristofanilli | C. Arroyo | A D Seidman | M Moasser | M. Fornier | F J Esteva | V. Currie | M E Moynahan | M N Fornier | L Tan | S Kaptain | A Bach | C Arroyo | V Currie | T Gilewski | M Theodoulou | N Sklarin | M Dickler | G D'Andrea | E Rivera | C A Hudis | A. Bach | S. Kaptain | Stamatina Kaptain
[1] D. Visscher,et al. Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.
[2] D. Maia. Immunohistochemical assays for HER2 overexpression. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Slamon,et al. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.
[4] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[5] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[6] T. Fleming,et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .
[7] P. Ravdin,et al. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.
[8] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Slamon,et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.
[10] M. Sliwkowski,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.
[11] T. Yamamoto,et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.
[12] Persons Dl,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .
[13] B. Pestalozzi,et al. Trastuzumab in CSF. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[15] N. Hynes,et al. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. , 1993, British Journal of Cancer.
[16] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Gown,et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] B. Groner,et al. Overexpression of the c‐erbB‐2 protein in human breast tumor cell lines , 1989, Journal of cellular biochemistry.
[19] R. Finn,et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.
[20] J. Ingle,et al. Increased HER2 with U.S. Food and Drug Administration-approved antibody. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Vogel. First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody) , 2000 .
[22] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[23] B. Groner,et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.
[24] G. Tsongalis,et al. p185HER2 Overexpression in Human Breast Cancer Using Molecular and Immunohistochemical Methods , 2000, Cancer investigation.
[25] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.
[26] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Dowsett,et al. Assessment of HER2 status in breast cancer: why, when and how? , 2000, European journal of cancer.
[29] F. Waldman,et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.
[30] L. Deangelis,et al. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel , 1995, Cancer.
[31] S. Bull,et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Hudis,et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.